Aligos therapeutics announces pipeline update and upcoming presentations at the european association for the study of the liver's digital international liver congress 2021

-five scientific posters to be presented at upcoming easl ilc meeting - all 4 aligos chb development candidates continue to advance – stops™ molecule and cam drug candidates are currently being evaluated in chb subjects - aso and sirna drug candidates are on track to enter clinical development in h2 2021 and h1 2022, respectively -antiviral activity data from at least one cohort of chb patients for alg-010133 and alg-000184 expected to be presented in h2 2021
ALGS Ratings Summary
ALGS Quant Ranking